table of content
Table of Contents
Post-pandemic Era-Global Non-Insulin Therapies for Diabetes Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Alpha-glucosidase Inhibitors -Product Introduction and Major Company
1.1.2 Amylin Agonists -Product Introduction and Major Company
1.1.3 Biguanides -Product Introduction and Major Company
1.1.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors -Product Introduction and Major Company
1.1.5 Glinides / Meglitinides -Product Introduction and Major Company
1.1.6 GLP-1 Analogs / GLP-1 Agonists -Product Introduction and Major Company
1.1.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors -Product Introduction and Major Company
1.1.8 Sulfonylureas -Product Introduction and Major Company
1.1.9 Thiazolidinediones -Product Introduction and Major Company
1.1.10 Others -Product Introduction and Major Company
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Five-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
2.1 Regional Market Share in Terms of Sales (2018 & 2022 & 2026)
2.2 Regional Market Share in Terms of Revenue (2018 & 2022 & 2026)
2.3 Regional Market Share in Terms of Consumption (2018 & 2022 & 2026)
3 Global Non-Insulin Therapies for Diabetes Market Assessment by Type
3.1 Global Non-Insulin Therapies for Diabetes Sales by Type (2018-2028)
3.2 Global Non-Insulin Therapies for Diabetes Revenue by Type (2018-2028)
3.3 North America Non-Insulin Therapies for Diabetes Sales and Revenue by Type (2018-2028)
3.4 Asia Non-Insulin Therapies for Diabetes Sales and Revenue by Type (2018-2028)
3.5 Europe Non-Insulin Therapies for Diabetes Sales and Revenue by Type (2018-2028)
3.6 Middle East & Africa Non-Insulin Therapies for Diabetes Sales and Revenue by Type (2018-2028)
3.7 South America Non-Insulin Therapies for Diabetes Sales and Revenue by Type (2018-2028)
4 Historical & Forecast Global Non-Insulin Therapies for Diabetes Market Assessment by Application
4.1 Global Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
4.2 North America Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
4.3 Asia Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
4.4 Europe Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
4.5 Middle East & Africa Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
4.6 South America Non-Insulin Therapies for Diabetes Consumption and Consumption in Different Application Field (2018-2028)
5 North America
5.1 US Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
5.2 Canada Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
5.3 Mexico Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
6 Asia
6.1 China Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
6.2 Japan Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
6.3 India Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
6.4 Korea Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
6.5 Southeat Asia Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
7 Europe
7.1 Germany Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
7.2 UK Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
7.3 France Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
7.4 Russia Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
7.5 Italy Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
8 Middle East and Africa
8.1 Saudi Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
8.2 UAE Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
8.3 Egypt Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
8.4 Nigeria Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
8.5 South Africa Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
9 South America
9.1 Brazil Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
9.2 Argentina Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
9.3 Colombia Non-Insulin Therapies for Diabetes Sales, Revenue and Growth Rate (2018-2028)
10 Global Non-Insulin Therapies for Diabetes Average Price Trend
10.1 Market Price for Each Type of Non-Insulin Therapies for Diabetes in North America (2018-2028)
10.2 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Asia (2018-2028)
10.3 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Europe (2018-2028)
10.4 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Middle East & Africa (2018-2028)
10.5 Market Price for Each Type of Non-Insulin Therapies for Diabetes in South America (2018-2028)
11 Value Chain
11.1 Non-Insulin Therapies for Diabetes Value Chain Analysis
11.1.1 Upstream
11.1.2 Downstream
11.2 COVID-19 Impact on Non-Insulin Therapies for Diabetes Industry
11.2.1 Industrial Policy Issued Under the Epidemic Situation
11.2.2 Post-pandemic Era
11.3 Cost-Under the Epidemic Situation
11.3.1 Cost of Raw Material
11.4 Channel Analysis
11.4.1 Distribution Channel-Under the Epidemic Situation
11.4.2 Distributors
12 Major Players of Global Non-Insulin Therapies for Diabetes Market, Competitive Analysis
12.1 GSK
12.1.1 GSK Company Profiles and Company News
12.1.2 GSK Product Introduction
12.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.1.4 SWOT Analysis
12.2 Eli Lilly
12.2.1 Eli Lilly Company Profiles and Company News
12.2.2 Eli Lilly Product Introduction
12.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.2.4 SWOT Analysis
12.3 Sumitomo Dainippon Pharma
12.3.1 Sumitomo Dainippon Pharma Company Profiles and Company News
12.3.2 Sumitomo Dainippon Pharma Product Introduction
12.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.3.4 SWOT Analysis
12.4 Intarcia Therapeutics
12.4.1 Intarcia Therapeutics Company Profiles and Company News
12.4.2 Intarcia Therapeutics Product Introduction
12.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.4.4 SWOT Analysis
12.5 Luye Pharma Group
12.5.1 Servier Company Profiles and Company News
12.5.2 Servier Product Introduction
12.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.5.4 SWOT Analysis
12.6 Pfizer
12.6.1 Pfizer Company Profiles and Company News
12.6.2 Pfizer Product Introduction
12.6.3 Pfizer Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.6.4 SWOT Analysis
12.7 Merck
12.7.1 Merck Company Profiles and Company News
12.7.2 Merck Product Introduction
12.7.3 Merck Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.7.4 SWOT Analysis
12.8 Dong-A Pharmaceutical
12.8.1 Dong-A Pharmaceutical Company Profiles and Company News
12.8.2 Dong-A Pharmaceutical Product Introduction
12.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.8.4 SWOT Analysis
12.9 Luye Pharma Group
12.9.1 Luye Pharma Group Company Profiles and Company News
12.9.2 Luye Pharma Group Product Introduction
12.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.9.4 SWOT Analysis
12.10 Eurofarma
12.10.1 Eurofarma Company Profiles and Company News
12.10.2 Eurofarma Product Introduction
12.10.3 Eurofarma Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
12.10.4 SWOT Analysis
12.11 Geropharm
12.12 Alkem Labs
12.13 SatRx
12.14 Jiangsu Hansoh Pharmaceutical
12.15 Novo Nordisk
12.16 Emisphere
12.17 Uni-Bio Science Group
12.18 Takeda
12.19 3SBio
12.20 Jiangsu Hengrui Medicine
13 Global Non-Insulin Therapies for Diabetes Market, Competitive Landscape and Market Forecast
13.1 Key Companies Dominating the Global Non-Insulin Therapies for Diabetes Market
13.2 Concentration Ratio (CR5) of Global Non-Insulin Therapies for Diabetes Market (2018)
13.2.1 Market Share of Top 5 Players in Term of Revenue (2018)
13.3 Concentration Ratio (CR5) of Global Non-Insulin Therapies for Diabetes Market (2022)
13.3.1 Market Share of Top 5 Players in Term of Revenue (2022)
14 Conclusion
15 Methodology and Data Source
